Login or Register to view
Improving gut health. Backed by real science.
Transaction Summary
Ateria Health Ltd
-
Raising A$2.5M
-
Series B
-
A$3.50 per share
Investment Highlights
-
Large & growing global market with unmet consumer needs
-
Ground breaking & natural plant-based product
-
Product already in market
-
Backed by ASX listed biotechnolgy company for A$2.5M
Company Overview
-
UK based biotech company
Develops and distributes supplements for overall health
-
Successfully launched its first ground-breaking product
August 2022, JUVIA™ a supplement for irritable bowel syndrome (IBS)
-
Strategic investment
Investment from ASX listed company Immuron Ltd(ASX: IMC) of A$2.6M with option for further A$2.5M
-
Expert Board and Management team
Inventors remaining on the Medical Advisory Board
Gut health plays a key role in human health
Ateria Health Ltd (‘Ateria’) is a science-backed health and wellness company, focused on the gut microbiome’s role in improving human health.
Ateria was founded in the UK in 2016 by the principals of Scientific Venture Partners, and Professor John Hunter and Dr Rosemary Waring.
The company was formed following decades of scientific research into the links between gut bacteria – the microbiome – and a range of conditions including irritable bowel syndrome, coeliac disease, colitis, diabetes and obesity.
Ateria generated proof of concept data in human pilot studies demonstrating its product is safe and effective and concluded two clinical studies in Perth, Western Australia.
Products & Services
How JUVIA™ works
Most IBS treatments don’t work because each of us has a unique gut microbiome.
JUVIA™ Digestive Balance Formula is a groundbreaking food supplement that works with your gut flora.
Rather than introducing new bacteria to your system, JUVIA™ works with your gut flora by breaking down carbohydrates before they have a chance to cause problems in the gut.
JUVIA™ is backed by cutting-edge science and is both plant-based and sustainable and will be launched with a unique progress-tracking app for customers.
What customers are saying…
“When I look back, I cannot believe the happy person I am now was the same miserable person I was 2 years ago. I would no longer class myself as having IBS and can confidently say that my bowels have completely returned to my normal. Thank you ERME! ” – EP, Female
“I have suffered with IBS for as long as I can remember. After taking ERME, I have been able to enjoy my favourite foods without the negative consequences” – TS, Male
“Since taking ERME I have found I can eat the foods that used to upset my bowels. I now have control over what I do and feel much more confident” – SB, Female
“ERME has given me the confidence to go about my day-to-day life with ease and be able to free my mind up for other things in life. I have more confidence in being able to eat a wider variety of things too” – MH, Male
Transaction Overview
Ateria Health is raising £500,000 at £1.85 per share, offering the same price as strategic investor Immuron (ASX: IMC). All directors have participated.
Money raised will be used to drive UK sales through investment in digital marketing initiatives and accelerate launch activities in new markets including Australia.
Offer closing 16th of December 2022.
Use of funds
64%Launch Costs / Marketing
20%R&D (Clinical Trials)
16%Working Capital
Team
- Directors
-
Douglas Dundonald
Chairman
-
Neil Wickers
CEO
-
Rebecca Wilson
Director
-
Fred Edenius
Director
-
Harry Karelis
Director
